Marea Therapeutics

Executive Summary

Marea Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and cardiovascular diseases, with a focus on cardiometabolic risk factors such as severe hypertriglyceridemia and NASH. Its lead program targets a novel pathway to lower triglycerides and reduce liver fat, utilizing a once-weekly injectable formulation designed for improved efficacy and convenience. The company has raised $190 million in funding and is currently advancing its pipeline through Phase 2 trials. Marea's approach addresses significant unmet needs in cardiometabolic health, where current treatments have limited efficacy or tolerability. With strong preclinical and early clinical data, the company is positioned to potentially offer best-in-class therapies that could transform standard of care for patients with high cardiometabolic risk. Upcoming catalysts are expected to drive near-term value for Marea. The company is likely to report topline data from its ongoing Phase 2 trial in severe hypertriglyceridemia in late 2026, which could validate its novel mechanism and support progression to Phase 3. Additionally, positive data may enable the initiation of a Phase 3 program in NASH, a large and underserved market. Beyond clinical milestones, Marea may seek strategic partnerships or licensing deals to expand its pipeline or leverage its platform for additional indications. These events could significantly de-risk the company and attract further investment or collaboration interest.

Upcoming Catalysts (preview)

• Q4 2026Topline results from Phase 2 trial of lead candidate in severe hypertriglyceridemia65% success
• Q2 2027Initiation of Phase 3 trial for lead candidate in NASH70% success
• H2 2026Strategic partnership or licensing agreement for metabolic pipeline50% success